Masimo won the patent lawsuit against Apple!

Masimo Triumphs in Patent Infringement Case Against Apple

Masimo (NASDAQ: MASI) issued a statement regarding the ruling by the California Middle District Court on November 15, 2025. The court upheld the validity of Masimo Patent No. 10,433,776 and ruled that Apple infringed this patent, awarding Masimo $634 million in damages.

The company expressed its satisfaction with the ruling and thanked the court and jury for their attention to the case. This outcome is considered a significant victory for Masimo in its efforts to protect its innovations and intellectual property. The company emphasized that it will continue to defend its intellectual property rights in the future.

About Masimo

Masimo (NASDAQ: MASI) is a global company operating in the medical technology field, developing industry-leading monitoring technologies such as innovative measurement methods, sensors, patient monitors, and automation solutions. The company's mission is to enhance the quality of life, improve patient outcomes, reduce healthcare costs, and expand non-invasive monitoring solutions into new areas.

Masimo SET® Pulse Oximeter technology has been on the market since 1995 and has been shown to outperform other pulse oximeter technologies in over 100 independent studies. Masimo SET® is used by over 200 million patients worldwide each year and serves as the primary pulse oximetric technology in 10 top U.S. hospitals listed in Newsweek's World's Best Hospitals published in 2025.